Mechanism of Action of a Multi-Herbal Extract Blend (Karallief Easy Climb) in Supporting Joint Health
Interdependence Public Relations
The Autoimmune Association, the world’s leading nonprofit organization dedicated to autoimmune awareness, advocacy, education, and research, is partnering with Olympian Khamica Bingham to increase understanding and awareness of autoimmune disease.
Cedars-Sinai investigators have identified a gene that plays an essential role in the innate human immune system. The gene, NLRP11, helps activate the inflammatory response that tells the body’s white blood cells to go on the attack against a foreign presence.
A Roundup of the Latest Medical Discoveries and Faculty News at Cedars-Sinai
A multicenter study performed by a large international consortium that includes UT Southwestern has outlined a set of risk factors and outcomes for patients with autoimmune hepatitis (AIH) that recurs after liver transplantation. The findings, published in the Journal of Hepatology, represent a first step toward better managing and potentially preventing this uncommon condition.
The National Institutes of the Health (NIH) has awarded researchers at the Icahn School of Medicine at Mount Sinai a four-year grant to study the role of the human microbiome in rheumatoid arthritis, systemic lupus, and other autoimmune diseases. The grant is part of the NIH’s Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) program, which is designed to speed the discovery of new treatments and diagnostics. It will support the Microbiome Technology and Analytic Center Hub (Micro-TEACH), a multidisciplinary team of researchers at Icahn Mount Sinai and NYU Langone Health.
New research using a mouse model for multiple sclerosis has uncovered a potential new area to explore for possible treatments for autoimmune disorders.
Through analyzing human DNA samples in a large biobank, Penn Medicine researchers found associations between genetic variants with severe COVID and conditions involving blood clots and respiratory issues
Mountainside Medical Group has announced that Randolph Sanchez, M.D., has joined the practice, adding rheumatology to the medical group’s specialty offerings. Dr. Sanchez treats a variety of autoimmune diseases in adult patients that can affect the bones, joints, and muscles, causing pain, swelling and deformity.
Imaging at near-atomic resolution of a key immune protein commonly known as STING has revealed a previously unrecognized binding site that appears to be pivotal for launching immune attacks, UT Southwestern scientists report in a new study. The findings, published in Nature, could lead to new ways of manipulating STING to prompt stronger immune responses or stem its action in autoimmune diseases.
Here are some of the latest articles that have been added to the Clinical Trials channel on Newswise.
People who consume sugar and other carbohydrates in excess over a long period of time have an increased risk of developing an autoimmune disease.
Antiphospholipid syndrome (APS) is rare in children and known to cause inflammation and recurring, potentially fatal, blood clots. Researchers found that two-thirds of children with the autoimmune disease experienced additional symptoms not formally associated with APS, including low platelet counts, hemolytic anemia and livedo reticularis, a rash indicating abnormal blood flow to the skin. Investigators say the findings underscore the importance of creating pediatric-specific criteria for the diagnosis of APS.
Scientists at La Jolla Institute for Immunology (LJI) have found that people with Parkinson's disease have a clear "genetic signature" of the disease in their memory T cells. The scientists hope that targeting these genes may open the door to new Parkinson's treatments and diagnostics.
Long term exposure to air pollution is linked to a heightened risk of autoimmune disease, particularly rheumatoid arthritis, connective tissue and inflammatory bowel diseases, finds research published online in the open access journal RMD Open.
New research may help scientists locate immature cells in the central nervous system that could shed light on the causes of neurodegenerative diseases like multiple sclerosis—and autoimmune disease that affects the brain and nervous system—and allow for the development of better therapeutic treatments.
Don't miss these articles in our Staff Picks channel
Researchers found a unique immune cell plays a key role in the chronic inflammation and scarring in the lungs and skin of people with scleroderma, or systemic sclerosis. After injecting mice with biodegradable PLG nanoparticles, which are used in medical sutures, researchers found that the nanoparticles specifically targeted these inflammatory cells and prevented skin and lung fibrosis. Researchers say it's a promising step towards targeted treatment for patients with early scleroderma.
University of Utah Health researchers are leading a five-year, $22-million nationwide clinical trial for NMDA receptor encephalitis––a type of autoimmune encephalitis that prompts the immune system to mistakenly attack the brain, causing confusion, memory loss, seizures, and symptoms similar to bipolar disorder and other psychiatric conditions.
The ACR and the AAHKS released a summary of their updated guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Studying mice, researchers at Washington University School of Medicine in St. Louis have discovered that roseolovirus can trigger autoimmunity in a previously unknown way: by disrupting the process by which immune cells learn to avoid targeting their own body's cells and tissues.
Researchers at La Jolla Institute for Immunology (LJI) have discovered new genes in CD4+ "helper" T cell subset that are linked to risk of autoimmune diseases. As they work to shed light on the exact functions of these CD4+ T cell subsets, the researchers have uncovered major differences between donors based on genetics and how the cells may function in men and women.
The ACR is launching new initiatives to reduce racial disparities in lupus clinical trials: Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY) and new Continuing Medical Education (CME) for dermatologists and nephrologists.
A new study suggests that a single bout of exercise does not change the immune response to a coronavirus booster shot in people with rheumatic autoimmune diseases. The article is published ahead of print in the Journal of Applied Physiology.
Quardricos Driskell joins executive team to lead efforts to champion patient-first policies
A new UC Davis Health study found that taking bile acids or treatments that regulate their production may help control inflammation caused by psoriasis, a chronic skin condition.
The latest research news from the Health Disparities Channel.
La Jolla Institute for Immunology (LJI) and Kyowa Kirin, Inc. (KKNA), a wholly-owned subsidiary of Kyowa Kirin Co., Ltd (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company, today announced the signing of a new collaboration agreement. The agreement marks another milestone in one of the most enduring industry-academic collaborations in the world.
A new, targeted therapy, developed by researchers from the Azrieli Faculty of Medicine of Bar-Ilan University, the Albert Einstein College of Medicine, the University of Houston, and the pharmaceutical company Equillium, together with several other academic collaborators, inhibits specific immune cells associated with lupus nephritis, and was effective in improving kidney inflammation in animal models of lupus and lupus nephritis. The new approach could serve as an alternative to current treatments targeting multiple immune cells, and provide a more effective and potentially personalized remedy for lupus nephritis. The development was recently reported in the Journal of Clinical Investigation.
A first-in-kind immune-modulating drug that arose from decades of basic research at UT Southwestern Medical Center has received approval from the U.S. Food and Drug Administration as a new treatment for adults with a form of myasthenia gravis. This rare and chronic autoimmune disease is characterized by debilitating and potentially life-threatening muscle weakness.
Two complementary studies show that defibrotide can successfully suppress the formation and progression of neutrophil extracellular traps, or NETs, which are web-like networks of toxic proteins that play a role in forming blood clots and promoting inflammation in several disease, including COVID-19. Researchers say findings may set the stage for defibrotide clinical trials in potentially several diseases.
Mayo Clinic researchers have linked the T cell dysfunction seen in rheumatoid arthritis with a metabolic deficiency in a new Nature Immunology publication.
About 7.5 million Americans suffer from psoriasis, an autoimmune disease that shows up as patches of red, inflamed skin and painful, scaly rashes. Although there are effective treatments for psoriasis, not everyone responds to these therapies—and for many, the relief is temporary.
People taking TNF inhibitors, a kind of immunosuppressive drug used to treat rheumatoid arthritis and other autoimmune conditions, produced a weaker and shorter-lived antibody response after two doses of Pfizer's COVID-19 vaccine, according to a study from Washington University School of Medicine in St. Louis. A third vaccine dose drove antibody levels back up, indicating that this additional dose may provide protection as the virus's delta variant continues to spread.
The Perelman School of Medicine at the University of Pennsylvania will continue to be on the leading edge of autoimmune research and care with the launch of the Colton Center for Autoimmunity at Penn. The new center unites research and patient care programs across Penn to drive advances in autoimmune diagnosis, prognosis, and treatment.
A new discovery of a physiological mechanism of psychosomatic illnesses could open a new therapeutic avenue for treating chronic inflammatory conditions such as Crohn's disease, psoriasis, and other autoimmune conditions, by attenuating their memory trace in the brain.
While investigators have known that maternal and fetal outcomes of pregnancy among women with systemic lupus erythematosus (SLE) have improved over time, it is unknown whether the improved outcomes are shared equally among different racial and ethnic groups. Lupus has been shown to disproportionately affect minorities of childbearing age. A new study that includes researchers from Hospital for Special Surgery (HSS) presented today at the American College of Rheumatology (ACR) annual meeting shows that pregnancy outcomes in women with lupus have improved in all racial and ethnic groups over the past decade, but disparities still exist.
A new study by researchers at Hospital for Special Surgery (HSS) in New York City demonstrates over half of patients with rheumatic diseases who contracted COVID-19 during the pandemic and completed a COVID-19 survey, experienced so-called “long-haul” COVID, or prolonged symptoms of the infection, including loss of taste or smell, muscle aches and difficulty concentrating, for one month or longer.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that people with systemic autoimmune diseases do as well after lung or heart-lung transplants as those without any systemic causes of end-stage lung disease.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that nearly 30% of patients with lupus in a multi-ethnic and multi-racial study had a low response to the new COVID-19 vaccines.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that Black people living with systemic sclerosis may have more severe disease and worse prognosis than patients in other racial or ethnic groups.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows the majority of rheumatoid arthritis patients on an ultra-low dose of rituximab maintained low disease activity for up to 4 years, and rarely needed to switch to other biologic drugs.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that hydroxychloroquine does not appear to be associated with QTc interval prolongation.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that use of platelet inhibitors could be associated with a reduction in the occurrence of digital ulcers in people with systemic sclerosis.
NYU Langone rheumatologists are presenting their discoveries at the annual American College of Rheumatology conference, November 1 to November 9. The conference will be held virtually.
Patients with a rare form of scleroderma that causes more skin thickening have a greater chance of dying from related heart, lung and kidney problems, a new study found. This occurs despite the patient population taking drugs used to treat most people with scleroderma. Researchers say it is an opportunity for more targeted drug development.
Systemic lupus erythematosus (SLE), commonly referred to as simply “lupus”, is an autoimmune disorder where the body’s immune system attacks healthy tissue.
Armed with a novel strategy they developed for bolstering the body’s immune response, scientists at Albert Einstein College of Medicine have successfully suppressed HIV infections in mice—offering a path to a functional cure for HIV and other chronic viral infections. Their findings were published today in the Journal of Clinical Investigation.
Dr. David Beck, nationally known for his work studying a novel inflammatory disorder called VEXAS, joins NYU Langone’s Division of Rheumatology.
Some devastating diseases, like Alzheimer's and autoimmune conditions, are hard to diagnose correctly because doctors don’t yet know what genes or molecules to look for. But a new technique inspired by the Star Trek tricorder can spot disease without the clues, using infrared light and machine learning.